Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2850 - The correlation between MMR gene expression MSH2/MSH6 and VEGF A/VEGF B in gastro-esophageal cancer

Date

11 Sep 2017

Session

Poster display session

Presenters

Amelia Dracea

Citation

Annals of Oncology (2017) 28 (suppl_5): v595-v604. 10.1093/annonc/mdx391

Authors

A. Dracea1, M. Danciulescu2, A. Dricu3, F. Burada1, M. Ioana1

Author affiliations

  • 1 Human Genomics Laboratory, University of Medicine and Pharmacy of Craiova, 200349 - Craiova/RO
  • 2 Department Of Oncology, University of Medicine and Pharmacy of Craiova, 200349 - Craiova/RO
  • 3 Unit Of Biochemistry, University of Medicine and Pharmacy of Craiova, 200349 - Craiova/RO
More

Resources

Abstract 2850

Background

VEGF proteins are key regulators of angiogenesis and targeting VEGF A led to inhibition of new blood vessels formation, with important therapeutic effects in various cancers. The roles of VEGF B are controversial; this peptide expression seems to inhibit apoptosis by suppressing many apoptotic/cell death-related genes and to facilitate metastasis by inducing vascular leakiness, leading to a high degree of tissue hypoxia that consequently activates DNA damage signalling pathways. MSH2/MSH6 is an important complex of proteins in DNA mismatch repair system and their altered expression could represent a response to the rapidly growing number of replication errors in a tissue with a high index of proliferation.

Considering that in certain conditions, DNA damage response products, such as H2AX, promote tumor growth and angiogenesis, in the present study we aimed to identify a common pattern of expression behavior between MMR genes MSH2/MSH6 and VEGF components (VEGF A and VEGF B), in order to use these genes as diagnostic markers in gastro-esophageal cancer.

Methods

mRNA levels of MSH2, MSH6, VEGF A, VEGF B were evaluated in tumoral and peritumoral tissues samples biopsied from 36 patients using qRT-PCR with specific TaqMan gene expression assays.

Results

VEGF A/VEGF B and MSH2/MSH6 mRNAs were expressed in both tumour and peritumour mucosa, with a tendency of tumoral up-regulation for VEGF A and MSH2/MSH6. When comparing the differences between tumoral/peritumoral expression level among the studied genes, we found that MMR and VEGF have a similar pattern of expression as follows: VEGF A gene expression correlates with MSH2 (rho Spearman = 0.4562; p 

Conclusions

Our results indicate a possible crosstalk between DNA mismatch repair and VEGF signaling pathways, providing new insight into understanding the potential connection of VEGF B and MSH6 in carcinogenesis.

Clinical trial identification

Legal entity responsible for the study

University of Medicine and Pharmacy of Craiova, Romania

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.